Biopharma AI
By
Can Cambridge and A*STAR’s New AI Digital Twin Platform Transform $50Bn Pharma Manufacturing Efficiency Landscape?
Key Takeaways AI-Driven Digital Twin for PharmaThe newly launched platform integrates AI with real-time plant data to create…
Can IQVIA and Flagship Pioneering’s AI-Driven Alliance Unlock the Next $60B Wave of Breakthrough Biopharma?
Key Highlights AI-Powered Acceleration in Drug DevelopmentThe collaboration positions IQVIA’s Healthcare-grade AI® and data-driven analytics at the center…
Could Halda Therapeutics and VantAI’s $1B AI Alliance Redefine the Future of Cancer Drug Discovery?
Key Highlights Strategic Alliance to Advance Induced Proximity TherapiesHalda Therapeutics has entered into a collaboration with AI biotech…
Could Eli Lilly’s $1.3 Billion GPCR Deal with Superluminal Medicines Unlock a New Era in Targeted Therapeutics?
Key Highlights Eli Lilly Taps AI-Powered Drug Discovery in Landmark GPCR Agreement Eli Lilly has entered a global…
Is Novartis Deepening Its Bet on AI-Enabled Molecular Glue Degraders Through an Expanded Collaboration With Monte Rosa?
Novartis AG (SIX: NOVN; NYSE: NVS), a global leader in immunology and targeted therapies, has broadened its partnership…
Can DeepMind’s Demis Hassabis Slash Drug Discovery Timelines From Years to Months—And What Does That Mean for Pharma Startups?
Key Highlights: What Hassabis Says: A Turning Point for Drug DiscoveryDemis Hassabis, CEO of DeepMind, recently told Bloomberg…
